Lexaria Bioscience Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LEXX research report →
About the company
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream.
- CEO
- Richard C. Christopher
- IPO
- 2021
- Employees
- 7
- HQ
- Kelowna, BC, CA
Price Chart
- Market Cap
- $11.45M
- P/E
- -1.16
- P/S
- 31.12
- P/B
- 2.07
- EV/EBITDA
- -0.68
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2571.89%
- Net Margin
- -2589.65%
- ROE
- -190.06%
- ROIC
- -150.12%
- Revenue
- $705.92K · 52.05%
- Net Income
- $-11,901,841 · -105.37%
- EPS
- $-0.66 · -40.43%
- Op Income
- $-11,880,737
- FCF YoY
- -109.42%
- 52W High
- $1.55
- 52W Low
- $0.46
- 50D MA
- $0.64
- 200D MA
- $0.82
- Beta
- 0.34
- Avg Volume
- 135.04K
Get TickerSpark's AI analysis on LEXX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 26 | BUNKA CHRISTOPHER | other | 100,000 |
| Jul 30, 25 | BUNKA CHRISTOPHER | buy | 11,900 |
| Jul 29, 25 | BUNKA CHRISTOPHER | buy | 15,600 |
| Jul 29, 25 | McKechnie William Edward | buy | 5,000 |
| Jul 29, 25 | DOCHERTY JOHN MARTIN | buy | 5,376 |
| Jul 29, 25 | Carle Vanessa | buy | 750 |
| Jul 29, 25 | CHRISTOPHER RICHARD | buy | 15,000 |
| May 15, 25 | CHRISTOPHER RICHARD | other | 150,000 |
| May 15, 25 | BUNKA CHRISTOPHER | other | 11,000 |
| May 15, 25 | Carle Vanessa | other | 15,000 |
Our LEXX coverage
Recent articles, reports, and earnings notes.
No research on LEXX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LEXX report →Similar companies
Peers in the same neighborhood.